Total
0
Shares
Paradigm Biopharmaceuticals (ASX:PAR) - Interim Chairman, Paul Rennie
Interim Chairman, Paul Rennie
Source: Paradigm Biopharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Paradigm Biopharmaceuticals (PAR) sees a shake up to its leadership board, with CEO Paul Rennie transitioning from Managing Director to a non-executive role as Chairman
  • In the non-executive role, Paul Rennie will focus on the direction of the company, working to enhance the strategic relationships
  • Paradigm’s Chief Medical Officer, Dr Donna Skerrett, will assume the role of interim CEO
  • A global executive search is now underway for Paradigm’s next CEO, with potential candidates already identified
  • Paradigm Biopharmaceuticals last traded at $2.15 on November 19

Biopharmaceutical company, Paradigm Biopharmaceuticals (PAR) has seen a shakeup to its leadership board.

Paradigm’s CEO, Paul Rennie, is set to transition from his executive role as Managing Director to a non-executive role as Chairman, effective immediately.

In the non-executive role, Paul Rennie will focus on the direction of the company, working to enhance strategic relationships.

Paul Rennie said it has been a pleasure to have been the CEO and Managing Director of Paradigm Biopharmaceuticals.

“I look forward to my continued involvement with Paradigm in this new role – it is a very exciting period for Paradigm as it moves further into its global phase 3 pivotal trial in Osteoarthritis (which is a large market with poorly met needs),” he said.

Following this, Paradigm’s Chief Medical Officer, Donna Skerrett, will assume the role of interim CEO.

“Dr Skerrett is a very capable and talented person and knows the company very well,” Mr Rennie said.

“Her proven talents have gained the respect of the entire Paradigm team and will ensure a seamless transition.”

A global executive search is now underway for Paradigm’s next CEO, with a number of potential candidates already identified.

Paradigm Biopharmaceuticals last traded at $2.15 on November 19.
  


PAR by the numbers
More From The Market Herald

" Golden Deeps (ASX:GED) reports ‘very high’ grade mineralisation

Golden Deeps (GED) has reported high-grade copper-lead-silver-vanadium intersections at its Nosib Block prospect.
Raiz Invest (ASX:RZI) - CEO Australia & Group COO, Brendan Malone

" Raiz Invest (ASX:RZI) announces investment by Seven West Media (ASX:SWM)

Media giant Seven West Media (SWM) has taken an investment stake in Raiz (RZI), in order to accelerate the growth of the financial

" Frontier Resources (ASX:FNT) reports encouraging rock chip results

Frontier Resources (FNT) is reporting a number of encouraging results from a recent rock chip sampling program at its Gascoyne Project in Western

" Vection Technologies (ASX:VR1) announces $12m capital raise

Software company Vection Technologies (VR1) announced a $12 million capital raise to support its expansion plans and to strengthen its research and development